Literature DB >> 8496157

Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival.

S Tanaka1, K Saito, J C Reed.   

Abstract

The bcl-2 gene can potentially encode 26- and 22-kDa proteins that differ only in their carboxyl tails because of an alternative splicing mechanism. The larger of these proteins contains a hydrophobic transmembrane domain within its carboxyl terminus, resides (at least in part) in mitochondrial membranes and has been shown to prolong cell survival by blocking programmed cell death (also termed "apoptosis"). To explore the function of the shorter 22-kDa Bcl-2 protein that lacks a transmembrane domain, DNAs encoding p26-Bcl-2-alpha or p22-Bcl-2-beta were expressed in an interleukin-3 (IL-3)-dependent hematopoietic cell line 32D. In contrast to p26-Bcl-2 alpha that markedly prolonged cell survival, p22-Bcl-2-beta did not extend the survival of 32D cells when cultured in the absence of IL-3. Expression in 32D cells of a chimeric DNA that fused portions of the open reading frame common to Bcl-2-alpha and Bcl-2-beta (amino-acids 1-195) with sequences encoding the transmembrane and cytosolic domains of the IL-2 receptor-alpha protein resulted in production of a Bcl-2/IL-2R fusion protein that was capable of prolonging 32D cell survival in the setting of IL-3 withdrawal. Based on fractionation of cells to produce crude heavy membrane, light membrane, nuclei, and cytosolic preparations, much of the p22-Bcl-2-beta protein appeared to reside in the cytosol, whereas Bcl-2-alpha and the Bcl-2/IL-2R chimeric proteins were found exclusively in fractions that also contained the inner mitochondrial membrane protein F1-beta-ATPase. Taken together, these findings demonstrate the importance of membrane association for the function and intracellular targeting of the apoptosis-blocking Bcl-2 protein. Furthermore, despite the strong evolutionary conservation of the carboxyl regions of Bcl-2-alpha proteins observed previously for mammalian and avian species, these data suggest that a heterologous transmembrane domain can be substituted without loss of function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496157

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Bax-induced cytochrome c release from mitochondria depends on alpha-helices-5 and -6.

Authors:  Gerd Heimlich; Alastair D McKinnon; Katussevani Bernardo; Dieter Brdiczka; John C Reed; Renate Kain; Martin Krönke; Juliane M Jürgensmeier
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

2.  Auto-activation of the apoptosis protein Bax increases mitochondrial membrane permeability and is inhibited by Bcl-2.

Authors:  Chibing Tan; Paulina J Dlugosz; Jun Peng; Zhi Zhang; Suzanne M Lapolla; Scott M Plafker; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2006-03-29       Impact factor: 5.157

3.  Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1.

Authors:  N Pathan; C Aime-Sempe; S Kitada; S Haldar; J C Reed
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

Review 4.  Targeting cancer cell death with a bcl-XS adenovirus.

Authors:  J S Han; G Núñez; M S Wicha; M F Clarke
Journal:  Springer Semin Immunopathol       Date:  1998

5.  Comparison of the ion channel characteristics of proapoptotic BAX and antiapoptotic BCL-2.

Authors:  P H Schlesinger; A Gross; X M Yin; K Yamamoto; M Saito; G Waksman; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

6.  Bcl-2 mutants with restricted subcellular location reveal spatially distinct pathways for apoptosis in different cell types.

Authors:  W Zhu; A Cowie; G W Wasfy; L Z Penn; B Leber; D W Andrews
Journal:  EMBO J       Date:  1996-08-15       Impact factor: 11.598

7.  Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes.

Authors:  S Krajewski; S Bodrug; R Gascoyne; K Berean; M Krajewska; J C Reed
Journal:  Am J Pathol       Date:  1994-09       Impact factor: 4.307

8.  Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.

Authors:  S Krajewski; M Krajewska; A Shabaik; T Miyashita; H G Wang; J C Reed
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

9.  A nucleus-targeted alternately spliced Nix/Bnip3L protein isoform modifies nuclear factor κB (NFκB)-mediated cardiac transcription.

Authors:  Yun Chen; Keith F Decker; Dali Zheng; Scot J Matkovich; Li Jia; Gerald W Dorn
Journal:  J Biol Chem       Date:  2013-04-19       Impact factor: 5.157

10.  Expression and function of bcl-2 proteins in melanoma.

Authors:  Jürgen Eberle; Amir M Hossini
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.